跳至主要内容
临床试验/NCT04497129
NCT04497129已完成不适用

Randomized Multicenter Comparative Trial Evaluating the Impact of the ROMTECH PortableConnect Rehabilitation Device on Time to Recovery and Comprehensive Rehabilitation Outcomes Post Unilateral Total Knee Arthroplasty (TKA)

ROM Technologies, INC5 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2020年8月17日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
300
试验地点
5
主要终点
Range of Motion

研究概览

简要总结

ROMTech is focused on transforming the healthcare market by delivering lower extremity rehabilitation systems that are effective, efficient for patient use, cost-effective, and provide better patient outcomes while simultaneously decreasing rehabilitation and overall recovery times.

详细描述

The patented technology of the ROMTech PortableConnect can improve the rehabilitation protocol for lower extremities in shorter time periods. The focus of this study is to compare the effectiveness of the ROMTech PortableConncect device only rehabilitation program following total knee arthroplasty to an active comparator group of continuous passive motion with a standard of care combination HHPT and OPPT rehabilitation program. The technology used to develop the ROMTech PortableConnect device has been reported in a pilot study to tend to be highly effective in decreasing the recovery time of patients post TKA, as discussed in the findings from the pilot study with the ROMTech Pro Cycle. The expedited recovery resulting from use of the ROMTech rehabilitation technology is noted to be contributed to the ability of the ROMTech technology to achieve a more rapid range of motion in this patient population.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Male or female ≥18 years of age at screening visit.
  • •Documentation of a definitive diagnosis of osteoarthritis of the knee requiring total knee arthroplasty.
  • •Scheduled or willing to schedule TKA procedure within the timelines consistent with the study enrollment period. This includes up to a 28-day screening window prior to the scheduled surgery.
  • •Willing to consent to outpatient, home-based physical therapy, CPM, or the ROMTech protocol
  • •Able to provide written informed consent.
  • •Willing and able to participate in and complete all study assessments, questionnaires, and procedure

排除标准

  • •Inability to provide informed consent.
  • •Inability to understand and complete study related assessments and procedures.
  • •Other scheduled surgical knee procedures in addition to the TKA.
  • •Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the subject or the quality of the data.
  • •History of musculoskeletal or neurological disorders that limit physical function including but not limited to severe spine OA, contralateral leg issues limiting mobility, and other disorders as identified by the investigator
  • •Planned additional knee joint surgery within 3 months of the primary scheduled TKA

研究组 & 干预措施

ROMTech PortableConnect

Experimental

Rehabilitation Using the ROMTech PortableConnect Device

干预措施: ROMTech PortableConnect (Device)

Traditional Rehabilitation & Continuous Passive Motion Device

Active Comparator

Combination of OPPT and HHPT in conjunction with CPM device usage

干预措施: Traditional Rehabilitation and CPM Device (Device)

结局指标

主要结局

Range of Motion

时间窗: Week 9 (Follow-up)

Knee Flexion and Extension

Range of Motion

时间窗: Week 5

Knee Flexion and Extension

Range of Motion

时间窗: Week 4

Knee Flexion and Extension

Range of Motion

时间窗: Screening

Knee Flexion and Extension

Range of Motion

时间窗: Baseline

Knee Flexion and Extension

Range of Motion

时间窗: Week 1

Knee Flexion and Extension

Range of Motion

时间窗: Week 2

Knee Flexion and Extension

Range of Motion

时间窗: Week 3

Knee Flexion and Extension

Range of Motion

时间窗: Week 6

Knee Flexion and Extension

Range of Motion

时间窗: Week 7 (End of Treatment)

Knee Flexion and Extension

次要结局

  • Days to ambulate without assistive devices and/or assistance(Week 9 (Follow-up))
  • Timed up and go (TUG) performance(Week 9 (Follow-UP))
  • Knee swelling(Week 9 (Follow-up))
  • Ambulation using the 6 Minute Walk Test (6MWT)(Week 9 (Follow-up))
  • Knee pain as measured on a 10-point pain scale(Week 9 (Follow-up))
  • Lower extremity functionality as measured using the Lower Extremity Functionality Scale (LEFS)(Week 9 (Follow-up))
  • Days to return to activities of daily living(Week 9 (Follow-up))
  • Oxford Knee Score (OKS)(Week 9 (Follow-up))
  • Opioid usage(Week 9 (Follow-up))
  • Knee Injury and Osteoarthritis Outcome Score (KOOS)(Week 9 (Follow-up))
  • Timed up and go (TUG) performance(Screening)
  • Timed up and go (TUG) performance(Week 4)
  • Timed up and go (TUG) performance(Week 7 (End of Treatment))
  • Knee pain as measured on a 10-point pain scale(Screening)
  • Knee pain as measured on a 10-point pain scale(Baseline)
  • Knee pain as measured on a 10-point pain scale(Week 1)
  • Knee pain as measured on a 10-point pain scale(Week 2)
  • Knee pain as measured on a 10-point pain scale(Week 3)
  • Knee pain as measured on a 10-point pain scale(Week 4)
  • Knee pain as measured on a 10-point pain scale(Week 5)
  • Knee pain as measured on a 10-point pain scale(Week 6)
  • Knee pain as measured on a 10-point pain scale(Week 7 (End of Treatment))
  • Knee swelling(Screening)
  • Knee swelling(Baseline)
  • Knee swelling(Week 1)
  • Knee swelling(Week 2)
  • Knee swelling(Week 3)
  • Knee swelling(Week 4)
  • Knee swelling(Week 5)
  • Knee swelling(Week 6)
  • Knee swelling(Week 7 (End of Treatment))
  • Lower extremity functionality as measured using the Lower Extremity Functionality Scale (LEFS)(Screening)
  • Lower extremity functionality as measured using the Lower Extremity Functionality Scale (LEFS)(Baseline)
  • Lower extremity functionality as measured using the Lower Extremity Functionality Scale (LEFS)(Week 1)
  • Lower extremity functionality as measured using the Lower Extremity Functionality Scale (LEFS)(Week 2)
  • Lower extremity functionality as measured using the Lower Extremity Functionality Scale (LEFS)(Week 3)
  • Lower extremity functionality as measured using the Lower Extremity Functionality Scale (LEFS)(Week 4)
  • Lower extremity functionality as measured using the Lower Extremity Functionality Scale (LEFS)(Week 5)
  • Lower extremity functionality as measured using the Lower Extremity Functionality Scale (LEFS)(Week 6)
  • Lower extremity functionality as measured using the Lower Extremity Functionality Scale (LEFS)(Week 7 (End of Treatment))
  • Ambulation using the 6 Minute Walk Test (6MWT)(Screening, Baseline)
  • Ambulation using the 6 Minute Walk Test (6MWT)(Baseline)
  • Ambulation using the 6 Minute Walk Test (6MWT)(Week 4)
  • Ambulation using the 6 Minute Walk Test (6MWT)(Week 7 (End of Treatment))
  • Days to ambulate without assistive devices and/or assistance(Screening)
  • Days to ambulate without assistive devices and/or assistance(Baseline)
  • Days to ambulate without assistive devices and/or assistance(Week 1)
  • Days to ambulate without assistive devices and/or assistance(Week 2)
  • Days to ambulate without assistive devices and/or assistance(Week 3)
  • Days to ambulate without assistive devices and/or assistance(Week 4)
  • Days to ambulate without assistive devices and/or assistance(Week 5)
  • Days to ambulate without assistive devices and/or assistance(Week 6)
  • Days to ambulate without assistive devices and/or assistance(Week 7 (End of Treatment))
  • Days to return to activities of daily living(Screening)
  • Days to return to activities of daily living(Baseline)
  • Days to return to activities of daily living(Week 1)
  • Days to return to activities of daily living(Week 2)
  • Days to return to activities of daily living(Week 3)
  • Days to return to activities of daily living(Week 4)
  • Days to return to activities of daily living(Week 5)
  • Days to return to activities of daily living(Week 6)
  • Days to return to activities of daily living(Week 7 (End of Treatment))
  • Opioid usage(Screening)
  • Opioid usage(Baseline)
  • Opioid usage(Week 1)
  • Opioid usage(Week 2)
  • Opioid usage(Week 3)
  • Opioid usage(Week 4)
  • Opioid usage(Week 5)
  • Opioid usage(Week 6)
  • Opioid usage(Week 7 (End of Treatment))
  • Knee Injury and Osteoarthritis Outcome Score (KOOS)(Screening)
  • Knee Injury and Osteoarthritis Outcome Score (KOOS)(Baseline)
  • Knee Injury and Osteoarthritis Outcome Score (KOOS)(Week 1)
  • Knee Injury and Osteoarthritis Outcome Score (KOOS)(Week 2)
  • Knee Injury and Osteoarthritis Outcome Score (KOOS)(Week 3)
  • Knee Injury and Osteoarthritis Outcome Score (KOOS)(Week 4)
  • Knee Injury and Osteoarthritis Outcome Score (KOOS)(Week 5)
  • Knee Injury and Osteoarthritis Outcome Score (KOOS)(Week 6)
  • Knee Injury and Osteoarthritis Outcome Score (KOOS)(Week 7 (End of Treatment))
  • Oxford Knee Score (OKS)(Screening)
  • Oxford Knee Score (OKS)(Baseline)
  • Oxford Knee Score (OKS)(Week 1)
  • Oxford Knee Score (OKS)(Week 2)
  • Oxford Knee Score (OKS)(Week 3)
  • Oxford Knee Score (OKS)(Week 4)
  • Oxford Knee Score (OKS)(Week 5)
  • Oxford Knee Score (OKS)(Week 6)
  • Oxford Knee Score (OKS)(Week 7 (End of Treatment))

研究者

发起方
ROM Technologies, INC
申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验